AGP Executive Report
Last update: 11 hours agoCancer Care in Focus: The EMA CHMP has issued a positive opinion for pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) as perioperative treatment for resectable muscle-invasive bladder cancer, including a subcutaneous option (Keytruda SC/QLEX), with a final EU decision expected in Q4 2026—relevant for patients in Liechtenstein as well. Short Bowel Syndrome Update: Zealand Pharma’s glepaglutide (Zeydovio) won a positive CHMP opinion for adults with short bowel syndrome, aiming to reduce reliance on parenteral support; the company positions it as a major advance after more than a decade. Local Health Policy Debate: Liechtenstein’s abortion law vote has sparked a political standoff, with Parliament approving a 12-week time-limit regime by a narrow margin while the hereditary prince signals he will seek to block it. Access to Care via Funding: Norway Grants negotiations have restarted for Hungary, with planned funding earmarked for areas including health care—Norway, Iceland and Liechtenstein are part of the donor framework. Medical Tech & IP: A Unified Patent Court injunction blocks MGI Tech from selling CycloneSEQ sequencing systems across several European markets, including Liechtenstein, after an Oxford Nanopore patent dispute.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
